Medications Archives

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

March 21, 2022

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.

February 24, 2022

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).

February 18, 2022

ASH 2021: Deep Profiling of Chronic Lymphocytic Leukemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Dr. Charis Teh and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Background: Venetoclax is a highly effective treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that works by inhibiting the BCL2 protein. BCL2

February 16, 2022

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients without the high-risk mutation,17p deletion

August 27, 2021

CLL Society Webinar On Demand: Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise?

Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they

May 25, 2021

Pushing Therapeutic Boundaries in CLL

Pushing Therapeutic Boundaries in CLLJoint Live Web Broadcast with CLL Society and PeerView Institute Recorded on June 14, 2021 Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the

April 22, 2021

Making Modern Treatment Choices in CLL

Making Modern Treatment Choices in CLLOncology Nurse Insights on the Patient Journey and the New Era of Care Recorded on April 22, 2021 CLL Society and PeerView Institute jointly provided a web broadcast in association with the 47th Annual ONS Congress. This NCPD/ILNA-certified program used PeerView’s “Nursing Clinical Consults”

March 1, 2021

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Medications

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

ASH 2021: Deep Profiling of Chronic Lymphocytic Leukemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

CLL Society Webinar On Demand: Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise?

Pushing Therapeutic Boundaries in CLL

Making Modern Treatment Choices in CLL

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT